- NewsCategory：
- All Company news Industry news
common105One result
-
1018
HitGen Enters into DNA-Encoded Library Based D≈∞'>rug Discovery Resear×$γch Collaboration with Galβ≈≈apagos NV
HitGen Enters into DNA-Encoded Library ↔$α←Based Drug Discovery Research Collaboration with ★λ≈Galapagos NVTHURSDAY, OCTO✘≥★÷BER 17, 2019HitGen Inc. today ann'×ounced that it has entered into a drug disc"☆≤overy research collaboration wi↑£th Galapagos NV to identify poα™λtential small molecule leads a•gainst targets of interest t'•o Galapagos NV. In this collaboratiε₽on, HitGen will apply its< technology platform, baseεΩd on DNA-encoded library design, synth• ♣esis and interrogation, to discover novel lea₽®≥ds. Under the terms of the agreement•✘, HitGen will receive an u♦∑ndisclosed upfront payment and §∞βwill be eligible for milestone payments frσ¥¥®om Galapagos NV.“We are ¥☆delighted to enter thi✔&'s collaboration with Galapagos NV, a↑φ leading biotechnology company, <₹specializing in the discovery and developmen Ω₽ t of small molecule medi↔₽cines with novel modes of a≠•ction. We believe the collabo ©ration reinforces the role of HitG★en’s platform in the♥ rapidly developing fiel∞↔d of DNA-encoded chemistry. We will work clo≥®★±sely with Galapagos NV scientists to generate ne♠¥ ∏w small-molecule lead compounds for their resε×≥earch programs to help bring tran♦®☆sformative medicines to patients,” said Dr. Jinβ¥φ Li, Chairman of the Board aφ☆nd Chief Executive Officer of HitGen.“∏€≥↓We look forward to workingπ with HitGen and tap into their est§™ablished DEL technology platform to comp←¥lement our internal screening and d↕↑∑∞rug discovery technologies.” said Romain Gosmi>₩ni, Director Medicinal Chemistry at G↓₩©alapagos.information sourceβ':pharma focus AsiaThe origi€₽←αnal link:https:https://www.pharmafocuδ¥<sasia.com/news/hitgen-enteδ' ♥rs-into-dna-encoded-library-×÷based-drug-discovery-research-collabor÷ ↑™ation-with-galapagos-≥♥π≥nv2019 Asia-pacific pha±<Ωrma IP Leader Summit: http://en.zenseegroup.com/pα/510934/ will be held in&₹βnbsp;Beijing on Novembe →r 14-15, and will attract more t→εhan 500 industry experts f♠₩'rom domestic and foreign pharmace<π"÷utical companies, biotechnology companie>↑♠♣s, governments, associations, law£¶ firms, intellectual property agents and other ¶φ★companies to attend.Official regis≥☆tration and consultation channels:Co★¥≤ntact：AnnPhone: 021-65650305Email：Marketing@zen↑ε≤seegroup.comhttp://en.zenseegr✘oup.com/p/510934 -
1017
WindMIL Therapeutics and University o ↔♥f California, Irvine Anno←unce Collaboration to ∑•♣βCollect Bone Marrow from Patients ≈★λ÷with Gliomas
WindMIL Therapeutics and University of Ca$↓≥lifornia, Irvine Announce Collaboration to Collec<¶¥¶t Bone Marrow from P↑∑atients with GliomasWEDNESDAY, δ ΩOCTOBER 16, 2019WindMIL Therapeutics←∞ and the University of California, Irvi&λ☆✘ne (UCI) today announced that th↔↑e first patients have been ide↑ntified in an investigator-sponsored stud★±y for the collection of bone mar"©row from patients with gli♠≥§omas. The study will evaluate generating Ω>marrow infiltrating lymphoc♦¥ytes (MILs™) for these £±patients through WindMIL’s pΩ♣↑roprietary cellular activation and expansion prγ£ocess. The study is b♠™↔×eing conducted at UCI.“Patients su∏₩Ωffering with glioblastoma are iαγσ←n great need of new, p↓☆romising treatments that might advanc∞&e the current standard o ™∑f care,” said Daniela A. Bota, MD, PhD, λλ↔₹director of the UCI Health Comprehensive Brain ∏←≈λTumor Program, senior associate dea≤>≥n for clinical research, UCI School of Medicin§>e and clinical director, UCI Sue & Bill ©××↕Gross Stem Cell Research Center≤✔. “The University of Califor&α¶nia, Irvine is excited to play a key <£✘↔role in research that may lead to a§§"↓ clinical trial that ←β©♦enlists the immune system in novel βα€ ways to fight this terrible disease.”Gliσ"γomas are the most common o≤★¥f the malignant brain tumors. Gliφδ oblastoma, the most common glio♠ma, has a five-year survival <¥™of less than 5 percent. Additional treatment op ±tions are urgently needed for these×✘→π patients. Adoptive immunotherapy is a Ω±♠possible approach for gliomas and the use of MI∞γα≥Ls, a cell therapy t€δ§≥hat is naturally tumor-specific, <Ω↔•is one such treatment option.The bone ma∏<rrow is a unique niche in the immune system to '★which antigen-experienced memory T c<©✔≈ells traffic and are then maintained. WindMIL &≤φhas developed a proprietary p←★rocess to select, activate and expand these m¥&§emory T cells into MILs. Because memo♦ •ry T cells in bone marrow occu✔≥↓λr as a result of the immune system’s recognition Ω of tumor antigens, MILs are specifically suite↓©δd for adoptive cellular immunothera£≤py and are able to dir$¶ectly eradicate or facilitλ★₩ate eradication of each patient©↕’s unique cancer. WindMIL is ♥©↓currently studying MILs in muΩ←Ωltiple myeloma, non-small cell lσα↑ung cancer and squamous cell carcinoma of the h'♠↑ead and neck, and plans to expand into o""ther solid tumors.“WindMIL is looking forw✔✔✘ard to working with the University of姕 California, Irvine on this e™↓xciting project and is optimistic that MILs mβ↔≠₹ay offer the potential to help patients with t₽♣§hese hard-to-treat diseases,” said Monil Shah, Ph$§armD, MBA, Chief Development Offi ≥cer at WindMIL.information source:pharma f<±εocus AsiaThe original link:https://www.pharmafoc ↓usasia.com/news/windmil-therapeuti₹∑λcs-and-university-of-california-irvine-an ☆nounce-collaboration↔¶ -to-collect-bone-marrow-frγ★∏€om-patients-with-gliomas2019 Asia-pacif¶©≥ ic pharma IP Leader Summit: h♠α≠ttp://en.zenseegroup.com/>εp/510934/will be held in Beijin ®g on November 14-15, and will a&→✔ttract more than 500 industry experts fromλ≤ domestic and foreign±Ω pharmaceutical comp÷>∏anies, biotechnology companies, ♠♦$governments, associatio☆•×ns, law firms, intellectual prαoperty agents and other co§¶÷↓mpanies to attend.Official regist"εration and consultation channels:Contact：AnnPh"€ one: 021-65650305Email：Mark≥eting@zenseegroup.comhttp://en.zenseegγ♣∞αroup.com/p/510934/ -
1016
CRISPR Therapeutics and KSQ Therapeutics Announc¶✘£e License Agreement to ↓$Advance Companies’ Respective Cell Therapy P§ $rograms in Oncology
CRISPR Therapeutics an"™β♠d KSQ Therapeutics Annou↑©nce License Agreement to Advanceδ←× Companies’ Respective Cell Therapy Programs in O→ ncologyWEDNESDAY, OCTOBER 16, 2019CRISPR &☆Therapeutics, a biopharmaceutical company∏♦±§ focused on creating transformati₽λ×ve gene-based medici®♦nes for serious diseases, and KSQ Therapeutics, a biotechnology co≥"mpany using CRISPR technology to enable the c™≥♥←ompany’s powerful drug discovery eng₹™ine to achieve higher probabilit£§↓≠ies of success in drug development, to'♥¶₽day announced a license agreement wh≈≥≥ereby CRISPR Therapeutics will gain access ∏ to KSQ intellectual property (§∏&IP) for editing certain novel gene targets in itσ ¥s allogeneic oncology cell therapy progφ€rams, and KSQ will gain access to CRIS±εPR Therapeutics’ IP for editing novel g"∑✘±ene targets identified by KSQ<β as part of its curren¥£t and future eTILTM (engineered tumor infiltrat₩φ&"ing lymphocyte) cell programs. The™γπ financial terms of the agreement are not b§•eing disclosed.“We are thrilled to gain©♥£ access to CRISPR Therapeuticσ↑βs’ foundational IP estate t★♣γ hrough this agreemen₩&t,” said David Meeker, M.D., Chief Executive Of>£♣ficer at KSQ Therapeutics. “Our eTILTM progσ'↓'rams involve editing'∏♠£ gene targets in human TILs that were discovered $∑ at KSQ by applying our propr→ε•≤ietary CRISPRomics® approach to immu≈φ™ ne cells in multiple in vivo models. This agrγ↕₽eement clears an important path for♦∑"• us to be able to bring these programs throug✔¶h development and commerciaπ↕lization, leveraging CRISPR Thδ∑↔erapeutics’ proprietary editing technology.”The g✔←ene targets within the sco ↔pe of the license agreement were iden∑∑tified using KSQ’s proprietary CRISPRom→δics® drug discovery engine, which allows ¥genome-scale, in vivo val>×idated, unbiased drug discovery. These specifiα¶c targets were uncov☆÷ered in screens to identify genetic edits★♠ that could enhance the functionality and quality↓>> of adoptive cell therapies in oncology.“KSQ hasβ™λ♠ built an industry-leading platform ★÷★to screen for novel gene targets using its techno☆ logy, and has identified a group♣₽>↓ of targets that could help un©φlock the full potential of ado↔εptive cell therapy in oncol$ ogy,” said Samarth Kulkarni, Ph.D., €©Chief Executive Officer at CR ®ISPR Therapeutics. “As a result of this li∞δ cense agreement, CRISPR Therapeutics will have th∞γ↕→e opportunity to bri€∏ng these novel targe← ™ts into our leading alloge←αΩneic CAR-T development platform®→↑ to further strengthen our future programs i∏≥≥n this important thera€☆peutic area.”information&n♣↕ bsp;source:pharma focus AsiaThe original link:hγttps:https://www.pharmaf♠♠♥∞ocusasia.com/news/crispr-therapeutics-and-ksq-the"£∏✔rapeutics-announce-license-agreem"£ent-to-advance-companies-γ>≠Ωrespective-cell-therapy-programs-i¥★↕↕n-oncology2019 Asia-pacific pharma IP Leader Su☆ §mmit: http://en.zenseegroup.com/p/510934/&nb★€✔sp;will be held in Beijing ∑∏ on Novembγ>λ₹er 14-15, and will attract more than 500 indust" ry experts from domestic and foreσ <ign pharmaceutical companies, biotech✔nology companies, gov±₩γernments, associations, law firms, inte¶<$¶llectual property agents and other compan✘σαies to attend.Official re™gistration and consultation channels:Contac₩γγt：AnnPhone: 021-65650305Email：Mar¶↓keting@zenseegroup.comhttp://en.zen∞seegroup.com/p/510934/ -
1015
Shionogi enters into a new liβδcense agreement and research>δ ♠ collaboration for the treatment oΩ♠f mycobacterial diseases with Hsiri T× αherapeutics, Inc.
Shionogi enters into a new l≤≈γicense agreement and≥ € research collaboration for theφ♦♥ treatment of mycobacterial diseases ↑with Hsiri Therapeutics, Inc.MONDAY, OCT >↕®OBER 14, 2019Shionogi & Co., ∑←Ltd. today announced that it has entered i →nto a new license agreement with Hsiri T≈ herapeutics, Inc. (Head Offδ₩ ice: Media, PA, USA; President and CEO: William C'¶&laypool, M.D.; hereafter "Hs♦≠¶∑iri") regarding a co>←φ₹llaborative research and dev"♠÷ elopment program to disc•♣÷₹over and develop additional novel therapeut✘δics for non-tuberculous mycobacte♣±γrial (NTM) diseases and tuberculosis ☆↔(TB). This new collaboration will incl&✘£Ωude technology that compleme¥≤£nts Shionogi's earlier collaboration arrangemenφ€≈t with Hsiri.The new technology to be×↔β♠ licensed from Hsiri has a novel mechanism ₽of action, will be complementary to Shionogi'÷€s current research with H≠¶siri, and is anticipated ∏<☆±to be more effective tha≠δ©↕n current therapies for mycobacterial₩©& infections. Shionogi's strength in ♦✔<small molecule drug discov™±±≈ery and development in the antibacterial area $>± will support development of Hsiri's inn☆∑λovative therapeuticsε×< in this collaborativφ✔e program. Under the terms of t↑σhis agreement, Shionogi will have ¶βexclusive worldwide rights to develop, manuf≠♦↑'acture, and commercialize the compou> £nds generated from the collaboration. Hsiri will¶× receive an upfront license fee, potential ÷©∏development milestones, an∑∏•↑d royalty payments based on sales ↕ ♠from Shionogi.It is reported that the number of↔©↔ patients suffering from NTM ★αdiseases has been increasing, especially in de&≠veloped countries, in recent ✔Ω£years. There is a med∏≤ical need to develop nov✘σel anti-NTM drugs be♠γσcause of the long duration of÷¥' treatment and insufficient treatment outco×∞₩me of current therapeutics. TB is one ofα® the three major infectious diseases in the wγφ✔orld, and new cases of TB are estimated to be 1★§♣€0.4 million/year. Multidrug-resi✘®stant TB (MDR-TB) and extensively drug-resistant•♦>Ω TB (XDR-TB) have become a major pu©£blic health concern, and novel drugs for MDR-TBπ✔✘ and XDR-TB are anticipated.Shionλ♣ogi's research and developm ★ent targets infectious disease as one of its priβ∑ ority areas, and Shiono' ↔gi have positioned "protectiδ≤"ng people from the t§↑hreat of infectious diseases" as o±☆<ne of its social mission targets. T↑ hrough this cooperation, Shionogi strivγ♣ ∏es constantly to bring forth €>innovative drugs for the treatment of i↔πnfectious diseases, to protect the ™☆health of patients we serve.information&nbs♣♦¶∑p;source:pharma focus AsiaThe or♥π≥♠iginal link:https:https:https://www.p×&harmafocusasia.com/n&πews/shionogi-enters-into-a-new-license-aβ☆©♥greement-and-research-col→₩laboration-for-the-treatment-of-mycobacterial-←≈diseases-with-hsiri-therapeutics-inc2019 Asia-p↓↑acific pharma IP Leader S ←≤ummit: http://en.zenseegroup.com/p/510934/×≈Ω will be held in Beijing >®€↑ on November "'∏ 14-15, and will attract mo£₩↓σre than 500 industry experts from domestic and fo≥β£reign pharmaceutical companies, biotechnolog"© y companies, governments, associations, law firm↑÷$s, intellectual property agents and ot£ελ♥her companies to attend.Official>←∑∏ registration and consultat ®®ion channels:Contact：AnnPhone: 021-6φ€♣5650305Email：Marketing@zenseegro<up.comhttp://en.zenseegroup.com/p/510δ934/ -
1014
Advaxis and UCLA Enter Collaboration for Gliobla≤>stoma Immunotherapy Discovery Research
Advaxis and UCLA Ent←er Collaboration for Glioblastoma Immuno >≥therapy Discovery ResearchFRIDAY, OCTOBER 11,Ω♥ 2019Advaxis, Inc., a cli♦↔₽nical-stage biotechnologε₩₩y company focused on the ©§÷$discovery, development and commer' ∞÷cialization of immunotherapy products↔♣>, today announced a research collaboration agreem•↑ent with the University of Calif≠♣ornia Los Angeles (UCLA) to cond✘₹uct preclinical studies evaΩ₩★luating the Company’s Lm technology in mεγouse tumor models of gl<↑ioblastoma multiforme (GBM). Spec>₹δifically, the collaboratiε£ on with Dr. Vaithi Arumugaswami’s gr∞✘♦oup at UCLA’s Department of Mo↑•lecular and Medical Pharmacology will investi✔βgate anti-tumor immunity and ♦φanti-tumor responses genera"←λ©ted by Lm vaccines that express diveα>¥rse glioblastoma neoantigens.“We are exc≠ ↑Ωited that Dr. Arumugaswami and his c λolleagues at UCLA will investig÷φate the potential of our Lm technology platφ€form in GBM, one of the deadliest cancers,” saiε¥d Andres Gutierrez, Execu±¶♠tive Vice President and Chief Medica€∞↑l Officer of Advaxis. “Contrary to other tumor ty≠♠pes, GBM has not seen much success in target©÷πing by immunotherapeutic agents due to a low t≠✔φumor mutation burden, high tumor hete<♣β®rogeneity and presence of the blood brain b∏¥arrier, among other factors. Hence, Dr. Arλ÷★&umugaswami’s characterization of the ne δ® oantigen landscape and immune € ÷responses to Lm- constructγ↕↑←s may lead to the development of nove≥≈l therapies with clinical activity in ✔♣αthis elusive cancer.”infφφormation source:pharma focus Asiaπ βThe original link:https:httβ₽ps:https://www.pharmafocusasia.c→≤om/news/advaxis-and-ucla-enter-collaboration-fσαor-glioblastoma-immunotherapy-discover€ y-research2019 Asia-pacific pharma IP Leader S÷§λummit: http://en.zenseegroup.com/p/510934/will≠ be held in Beijing on£←★ November 14-15, and will &±≤attract more than 500 industry experts from doε¥mestic and foreign pharmaceutical companies, b∞∞iotechnology companies,≥¶ governments, associations, law firγσ¥ms, intellectual prope÷ ∞rty agents and other companies to attend.Offici∑™al registration and cons₽±ultation channels:Con←π$tact：AnnPhone: 021-65650305Email：Marketing® @zenseegroup.comhttp://en.zen≠↕seegroup.com/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016